Fig. 1
LINC00909 is highly expressed in human pancreatic ductal adenocarcinoma (PDAC) and associated with worse clinicopathological features and outcome. (A) Upregulation of LINC00909 in PDAC was verified using TCGA and GTEx data. (B) Analysis of data from the GEPIA database demonstrated that LINC00909 expression was overexpressed in lymphoid neoplasm diffuse large glioblastoma multiforme (GBM), B-cell lymphoma (DLBC), brain lower grade glioma (LGG), acute myeloid leukemia (LAML), pheochromocytoma and paraganglioma (PCPG), thymoma (THYM) and skin cutaneous melanoma (SKCM). (C) RT-qPCR revealed high expression of LINC00909 in human PDAC tissues compared with normal pancreas tissues (n = 20). (D) Representative images of LINC00909 CISH analysis in the normal pancreas tissues (n = 80) and PDAC tissues (n = 80). (E) The H-Score of CISH analysis confirmed that the expression of LINC00909 was upregulated in PDAC tissues. (F) Kaplan–Meier analyses representing the overall survival (OS) and disease-free survival (DFS) of patients with PDAC. These patients with high expression of LINC00909 in the GDPH cohort were associated with poor prognosis. (G) LINC00909 expression in PDAC was strongly correlated with advanced TNM stage, larger tumor size, poorer differentiation, and more lymph node metastasis. (H) Multivariate Cox regression analyses of 80 patients with PDAC from the GDPH cohort showed that high levels of LINC00909 served as an independent risk factor for OS and DFS. All *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. P-values were caculated by the non-parametric Mann–Whitney U-test in (A) and (B). P-values were calculated by two-tailed t-tests in (C) and (E). P-values were assessed by χ2 tests or Fisher’s exact tests in (G). P-values and the hazard ratios (HR) by the log-rank (Mantel–Cox) test are calculated in (H)